secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0000950170-24-106614
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo/Alligator Phase 1 ALG.APV-527 trial: 60% stable disease, 11+ month duration in breast cancer
--------------------------------------------------------------------------------

- Phase 1 data presented at ESMO: 9 of 15 evaluable patients (60%) achieved stable disease across solid tumors.
- Breast cancer patient with progressive disease at entry achieved SD for >11 months and dose-escalated twice.
- Colon cancer patient with sustained SD remains on study for over 4 months.
- No maximum tolerated dose identified; safety profile positive across all cohorts.
- Serum concentrations consistent with dose and preclinical predictions; biomarker analyses confirm biological activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024106614/0000950170-24-106614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024106614/apvo-20240916.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-106614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer